Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response

This study is enrolling participants by invitation only.
Information provided by (Responsible Party):
Gilead Sciences Identifier:
First received: October 4, 2011
Last updated: August 11, 2014
Last verified: August 2014

This Registry is designed to obtain long term data on subject who have failed to achieve sustained virologic response (SVR) while receiving at least one Gilead oral antiviral agent (OAV) in a previous Gilead-sponsored hepatitis C study.

Hepatitis C, Chronic

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Long Term Follow-up Registry Study of Subjects Who Did Not Achieve Sustained Virologic Response in Gilead-Sponsored Trials in Subjects With Chronic Hepatitis C Infection

Resource links provided by NLM:

Further study details as provided by Gilead Sciences:

Primary Outcome Measures:
  • Viral Activity [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]
    To characterize HCV viral sequences and the persistence or evolution of treatment emergent viral mutations in subjects who fail to achieve an SVR after treatment with a Gilead oral antiviral (OAV) containing regimen in a previous Gilead-sponsored hepatitis C study

Secondary Outcome Measures:
  • Clinical progression of liver disease [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]
    Clinical progression of liver disease will be assessed by review of clinical signs, symptoms and laboratory parameters (clinical chemistry, haematology, coagulation and alfa-feto protein).

  • Development of hepatocellular carcinoma (HCC) [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]
    Screening for the development of HCC will comprise of review of clinical signs and symptoms and laboratory parameters including alfa-feto protein.

Biospecimen Retention:   Samples Without DNA


Estimated Enrollment: 800
Study Start Date: September 2011
Estimated Study Completion Date: July 2023
Estimated Primary Completion Date: July 2023 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Subjects who have failed to achieve sustained virologic response (SVR) while receiving at least one Gilead OAV in a previous Gilead-sponsored hepatitis C study.


Inclusion Criteria:

  • Have previously participated in a Gilead-sponsored hepatitis C study and received at least one Gilead OAV;
  • Have failed to achieve an SVR in a previous Gilead-sponsored study, as defined in the original treatment protocol;
  • Provide written, informed consent
  • Be willing and able to comply with the visit schedule.

Exclusion Criteria:

  • Subject plans to start a new course of hepatitis C therapy including any investigational drug or device during the course of the follow-up Registry.
  • History of clinically-significant illness or any other major medical disorder that may interfere with subject follow-up, assessments or compliance with the protocol.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01457768

  Show 335 Study Locations
Sponsors and Collaborators
Gilead Sciences
Study Director: John McNally Gilead Sciences
  More Information

No publications provided

Responsible Party: Gilead Sciences Identifier: NCT01457768     History of Changes
Other Study ID Numbers: GS-US-248-0123, 2011-000946-39
Study First Received: October 4, 2011
Last Updated: August 11, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Gilead Sciences:
Hepatitis C
Sustained Virologic Response
Direct Acting Antiviral
Combination Therapy
Treatment experienced
Treatment naive
GS 9451
GS 5885
GS 5816
GS 7977

Additional relevant MeSH terms:
Hepatitis A
Hepatitis C
Hepatitis C, Chronic
Digestive System Diseases
Enterovirus Infections
Flaviviridae Infections
Hepatitis, Chronic
Hepatitis, Viral, Human
Liver Diseases
Picornaviridae Infections
RNA Virus Infections
Virus Diseases processed this record on November 25, 2014